- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on PD-1/L1 Inhibitor
Total 147 results
-
Johann Wolfgang Goethe University HospitalWithdrawnSDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV InhibitorsGermany
-
The Affiliated Hospital of Qingdao UniversityUnknownNSCLC Stage IV | PD-1 | ARID1AChina
-
Diwakar DavarMerck Sharp & Dohme LLC; Gateway for Cancer ResearchNot yet recruitingPD-1 Refractory Advanced MelanomaUnited States
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingChemotherapy Effect | Lung Cancer Stage IV | PD-1 Antibody | Lung Cancer Squamous CellChina
-
Shanghai Jiao Tong University School of MedicineCompletedOral Cancer | VEGFR2 Inhibitor | Programmed Cell Death 1 Inhibitor | Inductive TherapyChina
-
Pharvaris Netherlands B.V.Active, not recruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingGastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and SurgeryChina
-
Shanghai Jiao Tong University School of MedicineRecruitingChemotherapy | Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant TherapyChina
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Pharvaris Netherlands B.V.CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsBulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
-
West China HospitalRecruitingBRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal AntibodyChina
-
Shanghai Ninth People's Hospital Affiliated to...Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Chest HospitalUnknownChemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
-
Grifols Therapeutics LLCTerminatedType 1 Diabetes MellitusUnited States
-
Shandong New Time Pharmaceutical Co., LTDNot yet recruitingNSCLC | Non-small Cell Lung Cancer | PD-1China
-
Shanghai Jiao Tong University School of MedicineRecruitingOral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFRChina
-
Sun Yat-sen UniversityCompletedBrain Metastases | NSCLC Stage IV | PD-1 AntibodyChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsRecruitingNasopharyngeal Carcinoma | Surgery | PD-1China
-
Southern Medical University, ChinaTerminatedDisease Progression | Proteinuria | Renal Insufficiency,Chronic | Dose-Response Relationship,Drug | ACE Inhibitor | Angiotensin II Type 1 Receptor BlockersChina
-
Sun Yat-sen UniversityNot yet recruitingCervical Cancer | Chemotherapy Effect | Neoadjuvant Therapy | Programmed Cell Death 1 Receptor / Antagonists & Inhibitors
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
General and Teaching Hospital CeljeCompletedDiabetes Mellitus, Type 1 | Biomarkers | Endothelial Dysfunction | Arterial Stiffness | FMD | Incretins | Endothelial Progenitor Cells | SGLT 2 Inhibitors | Glucose Excursions | FPFSlovenia
-
RenJi HospitalRecruitingRadiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug ConjugatesChina
-
Shanghai Jiao Tong University Affiliated Sixth...RecruitingCervical Cancer | Radiotherapy | Neoadjuvant Chemotherapy | PD-1 AntibodyChina
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaboratorsRecruitingNasopharyngeal Cancer | Chemotherapy | Radiotherapy | PD-1 TherapyChina
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaboratorsRecruitingNasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | PD-1 TreatmentChina
-
Shanghai Municipal Health BureauUnknownProteinuria | Angiotensin II Type 1 Receptor Blockers | Chronic Kidney Insufficiency | Angiotensin-Converting Enzyme InhibitorsChina
-
Sun Yat-sen UniversityRecruitingMuscle-Invasive Bladder Carcinoma | Radiotherapy | Programmed Cell Death Protein 1 InhibitorChina
-
Chinese PLA General HospitalUnknownAtherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
-
Beijing Friendship HospitalNot yet recruitingLymphoma | Hemophagocytic Lymphohistiocytosis | PD-1 Antibody | Epstein-Barr VirusChina
-
CSL BehringCompletedCystic FibrosisBulgaria, Hungary, Poland, United Kingdom
-
Lei LiRecruitingCervical Carcinoma | Immunotherapy | Survival Outcomes | Adverse Events | Locally Advanced Cervical Cancer | Chemoradiotherapy | Immune Checkpoint Inhibitor | Anti-programmed Cell Death Receptor 1 | Early Stage Cervical CancerChina
-
CSL BehringCompletedEmphysema | Alpha1-proteinase Inhibitor DeficiencyAustralia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingOvarian Cancer | Neoadjuvant Chemotherapy | Anti-PD-1 | Neoadjuvant ImmunotherapyChina
-
Lei LiRecruitingRecurrent Cervical Carcinoma | Radiotherapy | Immune Checkpoint Inhibitors | Overall Survival | Anti-programmed Death-1 Antibody | Metastatic Cervical Carcinoma | Persistent Advanced Cervical Carcinoma | Objective Remission Rate | Progression-free Survival | Severe Adverse EventsChina
-
Shanghai Jiao Tong University School of MedicineCompletedOral Cancer | Induction Chemotherapy | Programmed Cell Death 1 Inhibitor | Inductive TherapyChina
-
Lei LiRecruitingRecurrent Cervical Carcinoma | Radiotherapy | Immunotherapy | Survival Outcomes | Immune Checkpoint Inhibitors | Objective Response Rate | Metastatic Cervical Carcinoma | Tislelizumab | Persistent Cervical Carcinoma | Anti-programmed Cell Death Receptor 1China
-
The Second Affiliated Hospital of Chongqing Medical...Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...Not yet recruitingChronic Hepatitis b | Anti-PD-1 Antibody | Peg-IFNαChina
-
The Second Affiliated Hospital of Chongqing Medical...Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...Not yet recruitingChronic Hepatitis b | Anti-PD-1 AntibodyChina
-
Yale UniversityMerck Sharp & Dohme LLCRecruitingPembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaMelanoma | Renal Cell Carcinoma | Metastatic Melanoma | Brain Metastases | Pembrolizumab | Lenvatinib | PD1/PD-L1 ExperiencedUnited States
-
Grifols Therapeutics LLCTerminatedCOVID-19United States, Brazil, Chile, Colombia, Mexico
-
Lei LiUnknownCamrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine CarcinomasChemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 AntibodyChina
-
Incyte CorporationActive, not recruitingCervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)France, United States, Japan, Belgium, Australia
-
Roswell Park Cancer InstituteRecruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Recurrent Head and Neck Squamous... and other conditionsUnited States
-
Incyte CorporationActive, not recruitingCervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditionsFinland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway